BD has announced U.S. FDA market authorization for BD MAX Vaginal Panel, a first-of-its-kind molecular test to detect the most...
-BD (Becton, Dickinson and Company) announced that it has received 510(k) clearance from the FDA for the BD Vaginal Panel on the BD COR System, a comprehensive diagnostic test that directly detects the three most common infectious causes of vaginitis using BD's high-throughput molecular diagnostic platform for large laboratories.
BioXcel Therapeutics, Inc. announced details regarding the planned design of its upcoming TRANQUILITY In-Care Phase III trial to evaluate BXCL 501, the company’s investigational proprietary, orally dissolving film formulation of dexmedetomidine, as a potential acute treatment for agitation associated with Alzheimer’s dementia (AAD) in the care setting